Tammy Fumiko Messias Takara and Maria Joao Esteves
Background: Meningococcal disease (MD) has high incidence in children less than four years followed by teenagers and Young adults, with high mortality and comorbidities.
Objectives: To review the recommendations of Neisseria meningitidis Serogroup B Vaccine around the world. Methods: Medical Literature non sitematic review in English and Portugues Languague in the last 20 years with the following MesH terms “Neisseria meningitidis Serogroup B Vaccine”.
Results: 16 papers were full read, of 20 selected. Article’s origins of some recognized international relevant institutions like FDA, CDC and WHO. There is a consensus regarding the immunological security 4CMenB vaccine (Bexero®).
Discussion: The lack of knowledge of serogroup B strains circulating in Portugal and epidemiological data limits a real estimate to this situation in this country and is not possible to evaluate its benefit cost. European countries are in the middle and low ranges incidence of this MD.
Conclusion: There is no consensus in different countries with similar epidemiology between each other and so with Portugal, on the cost-effectiveness relationship of introducing the vaccine for public funding. The specific studies in each region to evaluate the cost-effectiveness of the vaccine are necessary. Despite the lack of scientific evidence about the cost-effectiveness of vaccination, it is the only current way of prevention MD of serogroup B.